sever
acut
respiratori
syndromeassoci
coronaviru
sarscov
mediat
attach
receptor
engag
entri
via
spike
glycoprotein
sdepend
viral
entri
requir
presenc
primari
receptor
angiotensin
convert
ctype
lectin
dcsign
dcsignr
lsectin
act
attach
factor
promot
bind
subset
target
cell
sarscov
like
coronaviru
spike
glycoprotein
contain
two
leucin
isoleucin
heptad
repeat
locat
ctermin
third
glycoprotein
homolog
fusion
protein
influenza
hemagglutinin
ha
hiv
thought
drive
membran
fusion
interact
togeth
member
trimer
spike
pack
togeth
form
highli
stabl
structur
known
sixhelix
bundl
event
follow
receptor
engag
lead
sixhelix
bundl
format
less
defin
viral
entri
mediat
sarscov
exquisit
sensit
compound
abl
rais
ph
cellular
endosom
thu
phdepend
compon
appear
requir
cellfre
viral
infect
mediat
howev
sdepend
celltocel
fusion
occur
neutral
ph
furthermor
fusion
enhanc
acid
ph
therefor
appear
unlik
direct
requir
acid
condit
order
undergo
conform
rearrang
requir
sixhelix
bundl
format
seen
phdepend
fusion
protein
ha
contrast
cell
express
endogen
low
level
use
target
celltocel
fusion
treatment
glycoprotein
express
effector
trypsin
necessari
order
effici
fusion
observ
thu
hypothes
order
effici
cellfre
viru
infect
occur
similar
proteolyt
activ
requir
trypsin
mimic
activ
phdepend
cellular
proteas
henc
explain
sensit
compound
abl
rais
endosom
ph
precis
requir
role
glycoprotein
process
coronaviru
entri
membran
fusion
well
defin
mani
coronavirus
mous
hepat
site
howev
absolut
requir
infect
although
lack
cleavag
lower
smediat
cellcel
fusion
contrast
sarscov
overexpress
cell
matur
virion
predominantli
fulllength
unprocess
form
fig
lefthand
lane
howev
celltocel
fusion
mediat
sarscov
enhanc
pretreat
effector
cell
trypsin
thu
role
proteolysi
sarscov
trypsinlik
proteas
cellfre
viru
infect
examin
lentiviralbas
pseudovirion
incorpor
sarscov
lipid
coat
produc
cell
virion
term
hiv
sarscov
analysi
reveal
follow
pretreat
trypsin
ctermin
fragment
approxim
kda
detect
use
polyclon
sera
rais
ctermin
extracellular
portion
fig
middl
lane
fragment
size
would
expect
follow
process
predict
boundari
howev
rather
enhanc
titer
might
predict
process
viral
fusion
protein
influenza
ha
pretreat
hiv
sarscov
trypsin
led
reduct
infect
fig
mutagenesi
suggest
trypsinmedi
cleavag
inde
occur
basic
residu
around
predict
boundari
although
alter
site
dramat
alter
infect
titer
data
shown
hypothes
trypsin
proteolysi
mimic
action
endosom
proteas
thu
like
engag
cell
surfac
occur
prior
proteolysi
endosom
therefor
trypsin
activ
attempt
follow
attach
viru
cell
surfac
rather
solut
previous
demonstr
pretreat
cell
agent
abl
rais
ph
endosom
ammonium
chlorid
dramat
reduc
infect
mediat
sarscov
fig
howev
hiv
sarscov
particl
first
bound
cell
surfac
c
trypsin
activ
infect
occur
even
presenc
ammonium
chlorid
fig
similar
result
obtain
use
live
replic
compet
sarscov
viru
infect
vero
cell
thu
trypsin
treatment
enhanc
abil
mediat
membran
fusion
also
reliev
requir
acid
ph
viral
entri
process
lack
basic
residu
boundari
mutat
ala
longer
process
trypsin
give
kda
ctermin
fragment
data
shown
howev
mutant
still
activ
trypsin
cleavag
cell
surfac
overcom
block
infect
mediat
ammonium
chlorid
data
shown
thu
unlik
proteolyt
process
mediat
trypsin
lead
activ
infect
occur
boundari
rather
distinct
site
viru
mhv
contain
furin
cleavag
site
within
yield
subunit
b
c
abil
trypsin
treatment
overcom
ammonium
chlorid
inhibit
smediat
infect
suggest
lysosomotrop
agent
may
prevent
proteolysi
phdepend
endosom
proteas
thu
effect
variou
proteas
inhibitor
hiv
sarscov
well
live
sarscov
infect
examin
detail
leupeptin
inhibitor
serin
cystein
proteas
aprotinin
specif
inhibit
serin
cystein
proteas
respect
pepstatin
aspart
proteas
inhibitor
entri
hiv
pseudovirion
mediat
sarscov
effici
block
leupeptin
ic
respect
tabl
infect
mediat
vsvg
phdepend
viral
membran
fusion
protein
inhibit
either
leupeptin
tabl
likewis
mediat
either
test
envelop
tabl
infect
cell
transient
express
replicationcompet
sarscov
also
inhibit
leupeptin
similarli
ammonium
chlorid
result
fig
trypsin
treatment
virion
bound
cell
surfac
overcam
block
infect
mediat
pretreat
leupeptin
specif
endosom
cystein
proteas
mediat
sarscov
infect
examin
use
specif
inhibitor
cystein
proteas
zleuleuleufluoromethyl
keton
zlllfmk
inhibitor
cathepsin
b
l
effici
inhibit
infect
hiv
sarscov
hiv
vsvg
contrast
select
inhibitor
cathepsin
b
dramat
affect
infect
either
pseudoviru
tabl
result
suggest
cathepsin
l
cathepsin
b
play
critic
role
sarscov
smediat
entri
pretreat
target
cell
either
pepstatin
aprotinin
effect
infect
panel
rel
specif
inhibitor
cathepsin
l
activ
zphephech
f
zphetyrcho
zphetyr
tbu
chn
use
determin
role
cathepsin
l
viral
entri
inde
four
compound
potent
inhibit
hiv
sarscov
pseudotyp
infect
fig
contrast
inhibitor
found
effect
hiv
vsvg
entri
inhibitor
cathepsin
k
bocpheleunhnhconhnhleuz
significantli
less
effect
inhibit
sarscov
smediat
entri
although
high
concentr
inhibit
note
fig
whether
due
cross
inhibit
cathepsin
l
high
inhibitor
concentr
suggest
cathepsin
k
play
minor
role
activ
unclear
order
directli
address
role
cathepsin
l
novel
intervirion
fusion
assay
establish
order
allow
studi
smediat
membran
fusion
cellfre
environ
lentivir
pseudovirion
prepar
incorpor
either
sarscov
receptor
two
set
particl
mix
presenc
absenc
proteas
order
studi
requir
activ
glycoprotein
membran
fusion
potenti
order
quantifi
intervirion
fusion
bear
virion
packag
luciferas
report
gene
sarscov
envelop
particl
lack
report
gene
coincorpor
envelop
glycoprotein
subgroup
avian
sarcoma
leukosi
viru
aslva
env
follow
mix
two
viral
popul
particl
plate
hela
cell
lack
stabli
express
aslva
receptor
tva
thu
aslva
env
mediat
infect
cell
dual
aslvasarscov
particl
mediat
intervirion
fusion
express
particl
cell
transduc
luciferas
report
gene
encod
particl
henc
luciferas
activ
act
direct
measur
intervirion
fusion
addit
order
prevent
uptak
mix
virion
endosom
subsequ
activ
endogen
proteas
target
cell
pretreat
leupeptin
consequ
mix
two
popul
virion
led
result
luciferas
activ
hela
cell
fig
contrast
mix
two
popul
virion
sampl
treat
either
trypsin
recombin
cathepsin
l
effici
transduct
target
cell
luciferas
report
gene
observ
predict
lack
inhibit
specif
cathepsin
b
inhibitor
recombin
cathepsin
b
show
enhanc
intervirion
fusion
fig
enhanc
intervirion
fusion
cathepsin
l
found
phdepend
highest
level
fusion
seen
ph
contrast
littl
intervirion
fusion
observ
cathepsin
l
neutral
ph
convers
trypsin
effici
gave
intervirion
fusion
neutral
ph
data
shown
argu
ph
direct
effect
thu
appar
requir
cathepsin
l
activ
effici
smediat
entri
explain
sensit
compound
ammonium
chlorid
rais
endosom
ph
due
requir
bind
receptorposit
cell
treatment
trypsin
fig
hypothes
receptor
interact
may
requir
prior
proteolysi
inde
intervirion
assay
follow
mix
hiv
sarscov
saslva
env
hivluc
virion
incub
step
elev
temperatur
requir
order
proteolysi
enhanc
fusion
virion
incub
c
prior
trypsin
treatment
intervirion
fusion
observ
result
suggest
conform
chang
induc
bind
may
inde
requir
prior
proteolysi
overal
experi
suggest
new
paradigm
viral
entri
target
cell
name
sarscov
receptormedi
conform
chang
induc
exposur
cryptic
cleavag
site
within
viral
envelop
glycoprotein
cleavag
site
phdepend
cellular
proteas
necessari
order
fulli
activ
protein
membran
fusion
potenti
character
phenomena
like
highlight
step
activ
may
yield
target
specif
inhibitor
entri
inde
find
cathepsin
l
import
activ
proteas
sar
infect
suggest
cellular
proteas
target
therapeut
intervent
entri
process
describ
sarscov
protein
also
rais
question
whether
b
classic
defin
phdepend
virus
display
depend
due
requir
acid
proteas
activ
phinduc
structur
rearrang
commonli
assum
